Insmed Incorporated (INSM) earnings on August 6, 2026

Before the market opens Q2 2026

More Insmed Incorporated earnings

Prior outlook: Pessimistic Outcome: Missed

Insmed's stock surged dramatically, closing up over 33% after a very positive market reaction, despite no specific news being provided.

INSM price around the earnings

132.55

Change: +34.2%

2026-08-06, 20:00 UTC

Start of the measured window End of the measured window
98.79 111.72 124.66 137.59 98.79
Price series around the eventClosing price per minute from before the event to the end of the measured window.
August 6, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Pessimistic Outcome: Missed

Thesis published
Results released

Analysts cite +98% upside but 25% beat rate and -16.3% avg surprise contradict optimistic thesis; negative trend strength persists.

Context analyzed before publication

Trend
Consistent deterioration from -56.4 to -68.6 over six days; negative trend strength into event.

Analysts

Evidence

Analyst consensus
Strong buy
Consensus average (1-5)
1.22
Analysts covering the stock
22
Average price target
195.95
Lowest price target
140
Highest price target
243
Upside to price target
97.9%
Revenue growth
229.6%
Forward EPS
0.12
Trailing EPS
-5.77
Analyst moves in the last 60 days
5
  • Strong buy: 5
  • Buy: 18
  • Hold: 0
  • Sell: 0
  • Strong sell: 0
Strong buy
5
Buy
18
Hold
0
Sell
0
Strong sell
0
  • July 21, 2026 · BMO Capital: Initiates coverage (Outperform)
  • July 15, 2026 · Wells Fargo: Maintains rating (Overweight → Overweight)
  • July 10, 2026 · Guggenheim: Reiterates rating (Buy → Buy)
  • June 22, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
  • June 8, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)

News and sentiment

Evidence

Sentiment
Sentiment
Constructive
Mention volume
High
Normalized volume
99%
News
Sources (6)

Technicals

Evidence

Price when the context was analyzed
98.79
Average true range (ATR)
3.1%
Distance to 52-week high
-53.2%
14-day change (14d)
-7.4%
30-day change (30d)
-11.4%
30-day relative strength
-13.9%
SPY change (30d)
+2.5%
Nearest support
98.24
Distance to nearest support
0.6%
Nearest resistance
99.72
Distance to nearest resistance
0.9%
Volume accumulation ratio (14d / 46d)
0.78
  • Mid: 98.24 (0.6% away, 0.18 ATR, 16 touches)
  • Mid: 97.33 (1.5% away, 0.48 ATR, 13 touches)
  • Mid: 96.53 (2.3% away, 0.74 ATR, 12 touches)
  • Mid: 99.72 (0.9% away, 0.3 ATR, 17 touches)
  • Mid: 100.9 (2.1% away, 0.69 ATR, 11 touches)
  • Mid: 101.74 (3% away, 0.97 ATR, 24 touches)

Trends

Evidence

Average earnings surprise
-16.3%
  • May 7, 2026: actual EPS -0.76 vs estimate -1 (surprise +23.9%)
  • February 19, 2026: actual EPS -1.54 vs estimate -1.17 (surprise -31.9%)
  • October 30, 2025: actual EPS -1.75 vs estimate -1.37 (surprise -27.8%)
  • August 7, 2025: actual EPS -1.7 vs estimate -1.31 (surprise -29.6%)

Expected move

Implied move
+4.7%
Source
Options chain

Reactions over its last 20 earnings

Median move
2.2%
75th percentile move
4.9%
90th percentile move
15.3%
Up / down moves
10 / 10
Average up move
+5.8%
Average down move
-4.8%

Monitoring and close

What Insmed Incorporated reported

Status
Finished
Actual EPS-0.06
EPS estimate-0.68
EPS surprise+91.2%

Insmed posts record BRINSUPRI revenue in Q2 and raises annual guidance, keeping an optimistic outlook. Market contexts remain mixed.

Sources (12)

Pre-market second reading after the results

There is no second reading available for this event.

How the stock reacted

Outcome
Missed
Consolidated
+33.5%
Max favorable move (MFE)
0%
Max adverse move (MAE)
39.4%